Factors predict compliance with payer-led oncology clinical pathways
A study presented at this year’s ASCO Quality Care Symposium examined predictors of compliance with payer-led oncology clinical pathways.
The study included patients with one of several malignancies — including melanoma, breast cancer, lung cancer or colorectal cancer — treated in the first-line setting for metastatic disease.
“These findings would be of interest to policymakers focused on value-based cancer care,” Samyukta Mullangi, MD, MBA, third-year fellow in medical oncology at Memorial Sloan Kettering Cancer Center, and colleagues concluded.
In this video, Healio spoke with Mullangi about the study results and their potential implications.
Collapse
Mullangi S, et al. Abstract 7. Presented at: ASCO Quality Care Symposium; Sept. 30-Oct. 1, 2022; Chicago.
Read more about